Cassava Sciences (SAVA)
Market Price (12/27/2025): $2.175 | Market Cap: $105.1 MilSector: Health Care | Industry: Biotechnology
Cassava Sciences (SAVA)
Market Price (12/27/2025): $2.175Market Cap: $105.1 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -101% | Weak multi-year price returns2Y Excs Rtn is -137%, 3Y Excs Rtn is -176% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Alzheimer's Disease Treatment, Biopharmaceutical R&D, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -112 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -105% | ||
| Key risksSAVA key risks include [1] the clinical trial failure and discontinuation of its lead drug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -101% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Alzheimer's Disease Treatment, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -137%, 3Y Excs Rtn is -176% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -112 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -105% |
| Key risksSAVA key risks include [1] the clinical trial failure and discontinuation of its lead drug, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are the key points for why Cassava Sciences (SAVA) stock moved by -4.4% for the approximate time period from August 31, 2025, to December 27, 2025:
<b>1. Failed Alzheimer's Drug Trials and Program Discontinuation</b><br><br>
Cassava Sciences faced significant setbacks in its Alzheimer's drug program, with the Phase 3 ReThink-ALZ study of simufilam failing to meet its primary endpoints in November 2024. This led to the discontinuation of all Alzheimer's disease clinical studies, a factor that continued to weigh heavily on investor sentiment into 2025 and contributed to a significant stock plunge in October 2025.
<b>2. FDA Clinical Hold on New Indication Trial</b><br><br>
In 2025, the U.S. Food and Drug Administration (FDA) placed a full clinical hold on Cassava's proposed trial for simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy. This regulatory hurdle required additional preclinical data and protocol modifications, delaying the initiation of the proof-of-concept trial and disrupting strategic plans.
<b>3. Continued SEC Scrutiny and Financial Settlement Impact</b><br><br>
Ongoing scrutiny from the U.S. Securities and Exchange Commission (SEC) and a $40 million settlement in 2024 over alleged data manipulation continued to impact investor confidence in the company's scientific credibility and management stability throughout 2025.
<b>4. Unproven Strategic Pivot</b><br><br>
Following the abandonment of its primary Alzheimer's program, Cassava Sciences' strategic shift to explore simufilam in TSC-related epilepsy remained unproven by clinical trial results in 2025, contributing to investor uncertainty.
<b>5. Financial Constraints and Operational Losses</b><br><br>
Cassava Sciences experienced financial strain, including significant operational losses in 2024, which deepened investor skepticism into 2025. This highlighted the company's reliance on speculative research and the ongoing need for further capital.
Show moreStock Movement Drivers
Fundamental Drivers
The -27.1% change in SAVA stock from 9/26/2025 to 12/26/2025 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.99 | 2.18 | -27.09% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 48.31 | 48.31 | 0.00% |
| Cumulative Contribution | � |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SAVA | -27.1% | |
| Market (SPY) | 4.3% | 40.0% |
| Sector (XLV) | 15.2% | 20.6% |
Fundamental Drivers
The 24.6% change in SAVA stock from 6/27/2025 to 12/26/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.75 | 2.18 | 24.57% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 48.26 | 48.31 | -0.10% |
| Cumulative Contribution | � |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SAVA | 24.6% | |
| Market (SPY) | 12.6% | 24.0% |
| Sector (XLV) | 17.0% | 20.7% |
Fundamental Drivers
The -15.8% change in SAVA stock from 12/26/2024 to 12/26/2025 was primarily driven by a -0.7% change in the company's Shares Outstanding (Mil).| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.59 | 2.18 | -15.83% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 47.98 | 48.31 | -0.69% |
| Cumulative Contribution | � |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SAVA | -15.8% | |
| Market (SPY) | 15.8% | 18.6% |
| Sector (XLV) | 13.3% | 19.4% |
Fundamental Drivers
The -92.4% change in SAVA stock from 12/27/2022 to 12/26/2025 was primarily driven by a -20.6% change in the company's Shares Outstanding (Mil).| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 28.67 | 2.18 | -92.40% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 40.05 | 48.31 | -20.62% |
| Cumulative Contribution | � |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SAVA | -90.3% | |
| Market (SPY) | 48.0% | 14.6% |
| Sector (XLV) | 18.2% | 8.1% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SAVA Return | 31% | 541% | -32% | -24% | -90% | -6% | -57% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| SAVA Win Rate | 42% | 58% | 33% | 33% | 42% | 67% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| SAVA Max Drawdown | -61% | 0% | -63% | -57% | -90% | -50% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See SAVA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | SAVA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -90.7% | -25.4% |
| % Gain to Breakeven | 970.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -78.9% | -33.9% |
| % Gain to Breakeven | 373.0% | 51.3% |
| Time to Breakeven | 120 days | 148 days |
| 2018 Correction | ||
| % Loss | -92.8% | -19.8% |
| % Gain to Breakeven | 1288.2% | 24.7% |
| Time to Breakeven | 641 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -99.9% | -56.8% |
| % Gain to Breakeven | 112800.0% | 131.3% |
| Time to Breakeven | 851 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Cassava Sciences's stock fell -90.7% during the 2022 Inflation Shock from a high on 7/28/2021. A -90.7% loss requires a 970.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are two analogies to describe Cassava Sciences (SAVA):
Analogy 1: A clinical-stage biotechnology company focused on Alzheimer's, akin to a much smaller, earlier-stage Biogen, but with its lead drug candidate under intense scrutiny and allegations regarding the integrity of its scientific data, creating an extremely high-risk, high-reward investment.
Analogy 2: Like a pharmaceutical startup, reminiscent of an early-stage Nikola (NKLA), where its entire market valuation is tied to a single, experimental Alzheimer's drug whose foundational claims are battling serious public allegations of scientific misconduct and data integrity issues.
AI Analysis | Feedback
- Simufilam: An investigational oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease.
- SavaDx: An investigational blood-based diagnostic test being developed to detect Alzheimer's disease.
AI Analysis | Feedback
Cassava Sciences (SAVA) is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, primarily simufilam for Alzheimer's disease. As a clinical-stage company, it does not currently have any commercialized products on the market.
Therefore, Cassava Sciences does not have "major customers" in the traditional sense, whether they be other companies or individual consumers. Its activities are primarily research and development, funded by investors, and it is not generating revenue from product sales. Consequently, there are no customer companies or categories of individual customers to list at this time.
AI Analysis | Feedback
- Catalent, Inc. (CTLT)
AI Analysis | Feedback
Richard J. Barry, President & Chief Executive Officer
Richard J. Barry was appointed Chief Executive Officer of Cassava Sciences in September 2024, after serving as Executive Chairman of the Board since July 2024. He has been a Director of Sarepta Therapeutics, Inc. since June 2015. Mr. Barry has extensive experience in investment management, having been a founding member, Managing General Partner, and Portfolio Manager of Eastbourne Capital Management LLC from 1999 to 2010. Prior to that, he was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management.
Eric Schoen, Chief Financial Officer
Eric Schoen has served as Cassava Sciences' Chief Financial Officer since 2018. Before joining the company, Mr. Schoen was Vice President, Senior Vice President, Finance, and Chief Accounting Officer of Aspira Women's Health Inc. (formerly Vermillion, Inc.), a publicly-held women's health company, from 2011 to 2017. He began his career at PricewaterhouseCoopers, where he spent nine years in audit and assurance, transaction services, and global capital markets practices.
Joseph Hulihan, Chief Medical Officer
Dr. Joseph Hulihan was appointed Chief Medical Officer in August 2025. He brings over 25 years of industry experience, specializing in the development of therapeutics for epilepsy and other neurological disorders. From 2019 to 2025, he served as Chief Medical Officer at Marinus Pharmaceuticals, where he led development programs in rare pediatric epilepsies and for the treatment of status epilepticus. Marinus Pharmaceuticals was acquired by Immedica Pharma in March 2025. Dr. Hulihan also held senior leadership roles in neuroscience drug development and medical affairs at Johnson & Johnson for 15 years.
R. Christopher Cook, Chief Operating and Legal Officer
R. Christopher Cook became Cassava Sciences' Chief Operating and Legal Officer in April 2025, having initially joined the company as Senior Vice President and General Counsel in October 2022. His prior experience includes serving as the Global Head of Litigation and Government Investigations for Alcon, a publicly traded medical device and pharmaceutical company. He also held the position of Vice President and division General Counsel for Walmart Central America and was a litigation partner at Jones Day for seventeen years.
Michael Zamloot, Senior Vice President, Technology Operations
Michael Zamloot has been Cassava Sciences' Senior Vice President, Technology Operations since 2000. He possesses 35 years of pharmaceutical industry experience with multinational firms and development-stage biopharmaceutical companies. His responsibilities encompass all aspects of Pharmaceutical Development, Quality, and Supply Chain Management. Mr. Zamloot is also an inventor on more than 25 patents.
AI Analysis | Feedback
The key risks to Cassava Sciences (SAVA) are as follows:
- Clinical Trial Failure and Discontinuation of Lead Drug Candidate: Cassava Sciences' primary drug candidate, simufilam, failed to meet its primary and secondary endpoints in its Phase 3 RETHINK-ALZ clinical trial for mild-to-moderate Alzheimer's disease. This led to the discontinuation of all development efforts for simufilam in Alzheimer's, including another Phase 3 trial and an open-label study, effectively ending its most significant program. The trial's results showed no significant improvement in cognition or daily functioning compared to a placebo.
- Regulatory Scrutiny and Allegations of Data Manipulation: The company has faced intense regulatory scrutiny from the Securities and Exchange Commission (SEC) and the Department of Justice (DOJ). Cassava Sciences agreed to pay $40 million to resolve an SEC investigation into allegations of misleading investors with doctored data from a Phase 2b clinical trial of simufilam. Additionally, a co-developer of the drug was separately charged by the SEC for allegedly manipulating data. These issues have raised significant concerns about the company's scientific credibility.
- Financial Vulnerability and Lack of Revenue Prospects: With the discontinuation of simufilam for Alzheimer's, Cassava Sciences currently has no approved products and no immediate revenue streams. The company has been burning cash, with operational losses of $63.1 million in 2024. While Cassava has cash and cash equivalents, its cash runway is projected into 2026 or early 2027, and it may require additional funding, which could lead to shareholder dilution. The company is exploring a new indication for simufilam (TSC-related epilepsy), but this program is in preclinical stages and remains unproven.
AI Analysis | Feedback
- Ongoing scientific and regulatory investigations into allegations of data manipulation and scientific misconduct related to Cassava Sciences' lead drug candidate, simufilam. These investigations, involving bodies like the FDA and NIH, could lead to adverse findings, impacting simufilam's clinical trials, regulatory approval prospects, and the company's overall viability.
- The increasing market penetration and regulatory validation of competing amyloid-targeting Alzheimer's drugs, such as Biogen/Eisai's Leqembi (lecanemab) and Eli Lilly's donanemab. These therapies are establishing a clear benchmark for efficacy and a validated treatment paradigm in Alzheimer's, creating a high competitive barrier for Cassava Sciences' simufilam, which utilizes a different, less established mechanism of action, especially if its Phase 3 results do not demonstrate superior efficacy or safety.
AI Analysis | Feedback
nullAI Analysis | Feedback
Cassava Sciences (SAVA) is a clinical-stage biotechnology company with its future revenue growth primarily tied to the successful development and commercialization of its lead drug candidate, simufilam, for Alzheimer's disease. Over the next 2-3 years, the expected drivers of revenue growth are:- Regulatory Approval and Commercial Launch of Simufilam: The most significant driver of future revenue for Cassava Sciences is the potential regulatory approval and subsequent commercial launch of simufilam as a novel treatment for Alzheimer's disease. The company has completed the last patient visit for its Phase 3 RETHINK-ALZ trial, with top-line results anticipated before the end of 2024. Successful trial outcomes are crucial for gaining regulatory approval and initiating sales. Cassava Sciences has already begun preparing for potential commercialization, indicating their readiness to bring the drug to market if approved.
- Market Penetration and Patient Adoption of Simufilam: Following a potential regulatory approval, the growth in revenue will depend on the company's ability to effectively penetrate the Alzheimer's treatment market and drive patient adoption of simufilam. The size of the Alzheimer's market presents a substantial opportunity. The company's discussions on the implications of their trials for Alzheimer's treatment suggest a focus on positioning simufilam competitively to gain market share.
- Expansion of Manufacturing and Commercial Infrastructure: In anticipation of successful trial results and commercialization, Cassava Sciences is expanding its manufacturing capabilities. An increase in research and development (R&D) spending is also expected in the second half of 2024 to support commercial launch preparations. These investments in infrastructure are essential to meet the demand and facilitate the distribution of simufilam, thereby enabling revenue growth.
- Development and Commercialization of Companion Diagnostics: Beyond the drug itself, Cassava Sciences has indicated a focus on diagnostics development. If simufilam requires or benefits from a companion diagnostic to identify suitable patients or monitor treatment efficacy, the commercialization of such diagnostics could represent an additional, albeit likely smaller, revenue stream.
AI Analysis | Feedback
Share Issuance
- In November 2020, Cassava Sciences completed an underwritten public offering of 9,375,000 shares of common stock at $8.00 per share, generating approximately $75.0 million in gross proceeds.
- In February 2021, the company closed a registered direct offering of 4,081,633 shares of common stock at $49.00 per share, resulting in gross proceeds of approximately $200.0 million.
- In November 2022, Cassava Sciences completed another registered direct offering of 1,666,667 shares of common stock at $30 per share, raising approximately $50 million in gross proceeds.
Capital Expenditures
- Cassava Sciences' capital expenditures for the latest twelve months were $74,000.
- Capital expenditures peaked in December 2021 at $22.214 million, subsequently decreasing to $2.712 million in 2022, $414,000 in 2023, and $103,000 in 2024.
- The company occupies approximately 25% of an office complex measuring about 90,000 rentable square feet as of December 31, 2024.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SAVA. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Cassava Sciences
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 9.1% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 16.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 21.4% |
| FCF/Rev LTM | 18.1% |
| FCF/Rev 3Y Avg | 18.6% |
Price Behavior
| Market Price | $2.18 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/14/2000 | |
| Distance from 52W High | -53.0% | |
| 50 Days | 200 Days | |
| DMA Price | $3.13 | $2.44 |
| DMA Trend | up | down |
| Distance from DMA | -30.3% | -10.6% |
| 3M | 1YR | |
| Volatility | 104.8% | 98.5% |
| Downside Capture | 415.74 | 119.42 |
| Upside Capture | 183.63 | 84.82 |
| Correlation (SPY) | 39.1% | 18.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.49 | 3.77 | 2.65 | 2.38 | 0.95 | 1.18 |
| Up Beta | 2.20 | 2.68 | 2.88 | 2.03 | 0.70 | 1.24 |
| Down Beta | 1.97 | 3.98 | 4.26 | 2.97 | 1.02 | 0.59 |
| Up Capture | 425% | 518% | 348% | 367% | 94% | 36% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 10 | 21 | 29 | 60 | 115 | 333 |
| Down Capture | 375% | 330% | 153% | 190% | 116% | 110% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 20 | 33 | 62 | 127 | 410 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of SAVA With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| SAVA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -7.2% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.3% |
| Annualized Volatility | 98.5% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 0.36 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 19.4% | 18.3% | 8.3% | 11.5% | 20.9% | 18.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of SAVA With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| SAVA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -23.7% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 135.5% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.46 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 7.6% | 16.6% | 4.0% | 7.6% | 9.8% | 13.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of SAVA With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| SAVA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -16.4% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 153.0% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.56 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 11.1% | 14.0% | 1.4% | 6.9% | 8.7% | 8.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | 4.8% | -10.3% | -5.8% |
| 8/14/2025 | 5.7% | -6.1% | -7.5% |
| 3/3/2025 | 3.3% | 17.1% | -37.5% |
| 11/7/2024 | -4.6% | -5.2% | -87.9% |
| 8/8/2024 | -13.8% | -21.5% | -10.9% |
| 5/10/2024 | 1.9% | 14.3% | -7.0% |
| 2/28/2024 | -0.3% | -6.9% | -11.2% |
| 11/7/2023 | 4.3% | -8.8% | 1.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 4 |
| # Negative | 12 | 11 | 15 |
| Median Positive | 4.8% | 10.4% | 20.1% |
| Median Negative | -4.6% | -11.1% | -10.9% |
| Max Positive | 15.1% | 31.3% | 71.6% |
| Max Negative | -13.8% | -21.8% | -87.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11122025 | 10-Q 9/30/2025 |
| 6302025 | 8142025 | 10-Q 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 3032025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8082024 | 10-Q 6/30/2024 |
| 3312024 | 5102024 | 10-Q 3/31/2024 |
| 12312023 | 2282024 | 10-K 12/31/2023 |
| 9302023 | 11072023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5012023 | 10-Q 3/31/2023 |
| 12312022 | 2282023 | 10-K 12/31/2022 |
| 9302022 | 11072022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 5052022 | 10-Q 3/31/2022 |
| 12312021 | 3012022 | 10-K 12/31/2021 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.